EUVIMEDEUVIMED entdecken
Crossref

Toward precision oncology: Leveraging bone metastatic organoid models for mechanistic, translational, and therapeutic discovery

Chencong Lv, Xiao Chen, Hongjing Dou, Zhenping Cao, Jiacan Su, Tong Meng

Organoid Research · 26.03.2026 · 2 (1) · 026050004

DOI: 10.36922/or026050004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organoid Research, online erschienen am 26.03.2026. Verfasst von Chencong Lv und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone metastasis represents a frequent late-stage complication in cancers such as lung, breast, and prostate, severely affecting patients’ quality of life. Conventional two‑dimensional cultures and animal models fail to recapitulate the complex bone microenvironment. Patient-derived organoids (PDOs) offer a physiologically relevant three-dimensional platform to recapitulate bone metastasis by preserving native tumor features and modeling tumor–bone interactions. This review systematically outlines the current methodologies for constructing bone metastatic organoid models, evaluates their applications, and identifies future directions. We describe the essential components of culture systems and critically discuss their strengths and limitations in modeling bone‑specific signaling. Furthermore, we highlight the capacity of PDOs to elucidate key aspects of bone metastasis, including tumor cell adaptation to the osseous niche, bidirectional remodeling of the microenvironment, and the dynamic monitoring of disease progression. Bone organoids are also discussed as a means of establishing a standardized bone microenvironment, offering a controllable in vitro platform for investigating interactions between tumor cells and the bone matrix. Furthermore, we present the translational potential of organoids for informing individualized therapy selection, evaluating clinical drug sensitivity, and facilitating the development of organoid biobanks. Looking forward, the development of patient-specific “bone metastasis-on-a-chip” systems with artificial intelligence-driven digital twins may transform the research paradigm from experimental simulation to precision prediction, ultimately advancing personalized therapeutic strategies for bone metastatic disease.

Zitieren

APA

Lv, C., Chen, X., Dou, H., Cao, Z., Su, J., & Meng, T. (2026). Toward precision oncology: Leveraging bone metastatic organoid models for mechanistic, translational, and therapeutic discovery. Organoid Research, 2(1), 026050004. https://doi.org/10.36922/or026050004

Vancouver

Lv C, Chen X, Dou H, Cao Z, Su J, Meng T. Toward precision oncology: Leveraging bone metastatic organoid models for mechanistic, translational, and therapeutic discovery. Organoid Research. 2026;2(1):026050004. doi:10.36922/or026050004

BibTeX
@article{Lv2026,
  author = {Lv, Chencong and Chen, Xiao and Dou, Hongjing and Cao, Zhenping and Su, Jiacan and Meng, Tong},
  title = {Toward precision oncology: Leveraging bone metastatic organoid models for mechanistic, translational, and therapeutic discovery},
  journal = {Organoid Research},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {026050004},
  doi = {10.36922/or026050004}
}
Kostenlos starten →